AGA Clinical Practice Update on Functional Heartburn: Expert Review.
Benchmarking
Complementary Therapies
Digestive System Surgical Procedures
/ adverse effects
Endoscopy, Gastrointestinal
/ adverse effects
Evidence-Based Medicine
Gastroesophageal Reflux
/ diagnosis
Gastrointestinal Agents
/ adverse effects
Healthy Lifestyle
Heartburn
/ diagnosis
Humans
Psychotherapy
Risk Reduction Behavior
Treatment Outcome
Ambulatory Reflux Monitoring
Functional Heartburn
High-Resolution Manometry
Nonerosive Reflux Disease
Journal
Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
03
12
2019
revised:
14
01
2020
accepted:
23
01
2020
pubmed:
6
2
2020
medline:
18
2
2021
entrez:
5
2
2020
Statut:
ppublish
Résumé
BEST PRACTICE ADVICE 1: A diagnosis of functional heartburn should be considered when retrosternal burning pain or discomfort persists despite maximal (double-dose) proton pump inhibitor (PPI) therapy taken appropriately before meals during a 3-month period. BEST PRACTICE ADVICE 2: A diagnosis of functional heartburn requires upper endoscopy with esophageal biopsies to rule out anatomic and mucosal abnormalities, esophageal high-resolution manometry to rule out major motor disorders, and pH monitoring off PPI therapy (or pH-impedance monitoring on therapy in patients with proven gastroesophageal reflux disease [GERD]), to document physiologic levels of esophageal acid exposure in the distal esophagus with absence of reflux-symptom association (ie, negative symptom index and symptom association probability). BEST PRACTICE ADVICE 3: Overlap of functional heartburn with proven GERD is diagnosed according to Rome IV criteria when heartburn persists despite maximal PPI therapy in patients with history of proven GERD (ie, positive pH study, erosive esophagitis, Barrett's esophagus, or esophageal ulcer), and pH impedance testing on PPI therapy demonstrates physiologic acid exposure without reflux-symptom association (ie, negative symptom index and symptom association probability). BEST PRACTICE ADVICE 4: PPIs have no therapeutic value in functional heartburn, the exception being proven GERD that overlaps with functional heartburn. BEST PRACTICE ADVICE 5: Neuromodulators, including tricyclic antidepressants, selective serotonin reuptake inhibitors, tegaserod, and histamine-2 receptor antagonists have benefit as either primary therapy in functional heartburn or as add-on therapy in functional heartburn that overlaps with proven GERD. BEST PRACTICE ADVICE 6: Based on available evidence, acupuncture and hypnotherapy may have benefit as monotherapy in functional heartburn, or as adjunctive therapy combined with other therapeutic modalities. BEST PRACTICE ADVICE 7: Based on available evidence, anti-reflux surgery and endoscopic GERD treatment modalities have no therapeutic benefit in functional heartburn and should not be recommended.
Identifiants
pubmed: 32017911
pii: S0016-5085(20)30128-1
doi: 10.1053/j.gastro.2020.01.034
pii:
doi:
Substances chimiques
Gastrointestinal Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2286-2293Informations de copyright
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.